CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital)

N/A

Report date: 2024/03/21 20:00:29

Base Information

Drug NameCD79b-19 CAR T Cells Therapy (Massachusetts General Hospital)
Drug Alias NameBivalent CD79b and CD19 Directed CAR T Cells Therapy (Massachusetts General Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD79B
TargetsB-lymphocyte antigen CD19B-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts General Hospital
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A